IRB #

STUDY00019801

Title

[NCI CIRB] - S1712 - A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease

Principal Investigator

Michael Heinrich

Study Purpose

The purpose of this study is to compare the good and bad effects of adding ruxolitinib to the standard chemotherapy vs. using the standard chemotherapy alone.

This study is also looking at the toxicities, progression free survival and overall survival rates in this patient population.

Medical Condition(s)

CML

Eligibility Criteria

1- Diagnosis of Chronic Phase CML without any history of progression to accelerated or blast phase CML.

2- Patients must have detectable BCR-ABL transcripts

3- Patients must be receiving treatment with dasatinib or nilotinib as first or second line therapy for a minimum of 6 months prior to registration.

4- Patients must not have received more than 2 TKI.

5- Patients must be expected to remain on the same TKI for the next 12 months

6- ≥ 18 years of age

7 - Labs within range

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

5 years from the time of registration

Minors Included

No

Contact

Knight Information Line - trials@ohsu.edu or 503-494-1080

Sponsor

SWOG

Recruitment End

04/30/2023

Compensation Provided

No


Go Back